AVDL AVADEL PHARMACEUTICALS PLC Investments/Divestments 8-K Filing 2023 - Underwriting Agreement for Public Offering Avadel Pharmaceuticals entered into an underwriting agreement for a registered public offering of ordinary shares and non-voting convertible preferred shares, with expected net proceeds of approximately $117.0 million.Get access to all SEC 8-K filings of the AVADEL PHARMACEUTICALS PLC